# Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

> **NCT01184807** · PHASE1 · COMPLETED · sponsor: **Otsuka Beijing Research Institute** · enrollment: 51 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** OPB-51602

## Key facts

- **NCT ID:** NCT01184807
- **Lead sponsor:** Otsuka Beijing Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01184807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01184807, "Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01184807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*